LS Investment Advisors LLC held its stake in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) during the second quarter, Holdings Channel reports. The fund owned 1,134 shares of the company’s stock at the end of the second quarter. LS Investment Advisors LLC’s holdings in Taro Pharmaceutical Industries were worth $127,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Bank of Montreal Can boosted its position in Taro Pharmaceutical Industries by 7.5% in the second quarter. Bank of Montreal Can now owns 2,128 shares of the company’s stock valued at $238,000 after buying an additional 149 shares during the last quarter. NN Investment Partners Holdings N.V. boosted its position in Taro Pharmaceutical Industries by 2.0% in the second quarter. NN Investment Partners Holdings N.V. now owns 53,976 shares of the company’s stock valued at $6,049,000 after buying an additional 1,064 shares during the last quarter. Finally, Creative Planning boosted its position in Taro Pharmaceutical Industries by 3.8% in the second quarter. Creative Planning now owns 7,186 shares of the company’s stock valued at $805,000 after buying an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 16.41% of the company’s stock.

Taro Pharmaceutical Industries Ltd. (TARO) traded up 1.35% during trading on Friday, reaching $98.57. 85,363 shares of the company’s stock traded hands. The firm’s 50 day moving average is $113.86 and its 200-day moving average is $112.80. Taro Pharmaceutical Industries Ltd. has a 12 month low of $92.28 and a 12 month high of $137.98. The company has a market capitalization of $3.99 billion, a price-to-earnings ratio of 10.04 and a beta of 0.64.

Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings results on Monday, May 22nd. The company reported $2.05 earnings per share (EPS) for the quarter. The business had revenue of $196.41 million for the quarter. Taro Pharmaceutical Industries had a net margin of 49.69% and a return on equity of 20.08%. Analysts expect that Taro Pharmaceutical Industries Ltd. will post $9.49 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.watchlistnews.com/taro-pharmaceutical-industries-ltd-taro-position-held-by-ls-investment-advisors-llc/1475862.html.

TARO has been the topic of several research analyst reports. BidaskClub cut shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research note on Friday, June 9th. TheStreet cut shares of Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a research note on Wednesday. Finally, Credit Suisse Group cut shares of Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a research note on Tuesday, May 23rd.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.